News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Valeant Pharmaceuticals International (VRX)'s Debate About Research Are Misleading, Wrong


6/13/2014 6:43:41 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

How can we trust Valeant’s calculations about whether it would create value by buying Allergan for $53 billion when Valeant’s presentation of basic facts about the drug industry is self-serving and misleading?

Hey, check out all the research scientist jobs. Post your resume today!

Read at Forbes

comments powered by Disqus
Forbes
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES